LiangyiHui Completes Hundreds of Millions RMB Series C+ Financing to Build an Innovative Digital Oncology Platform, Advised Exclusively by Haoyue Capital

VCBeat has learned that Liangyihui, an innovative digital healthcare platform in the oncology field, recently announced the completion of its C+ round financing, amounting to hundreds of millions of RMB. Previously, numerous leading investors in the healthcare sector had expressed confidence in Liangyihui’s business model and operational capabilities. In this round, Liangyihui introduced a leading investment institution and Shunwei Capital, a top-tier investor in the smart hardware sector, which will inject additional resources and capabilities into Liangyihui’s development. Existing shareholders, including Qiming Venture Partners and Danlu Capital, continued to participate in this round. Hywin Capital served as the financial advisor for this financing round.

Liangyihui completed a Series C financing round exceeding RMB 100 million at the beginning of this year. This funding will help Liangyihui further solidify its existing technology-, data-, and service-driven innovative digital platform for oncology, deeply connecting hospitals, associations, physicians, cancer patients, and pharmaceutical companies. By precisely matching the supply and demand of all parties involved in oncology drug development and disease treatment, the platform aims to ultimately provide cancer patients with more suitable diagnostic and treatment plans, as well as a more comprehensive healthcare service experience.

Liangyihui, established in 2015, has accumulated a user base of nearly 200,000 oncologists and close to 300,000 cancer patients, becoming one of China’s largest online platforms for oncology doctors and patients. It is a trusted partner for oncologists, patients, and enterprises alike. Liangyihui also collaborates extensively with major cancer hospitals to assist in patient education and management. Over the past six years, Liangyihui has evolved through content-led development, technological innovation, and data-driven strategies, establishing itself as one of the preferred online platforms for oncologists, patients, and healthcare companies.

Liangyihui has long leveraged product technology and data-driven strategies, in conjunction with its proprietary academic exchange platform, internet hospital platform, research collaboration platform, and patient management platform, to digitize and bring online traditional offline services such as medical education, healthcare delivery, patient services, and pharmaceutical marketing, thereby benefiting a broader population of oncology patients and healthcare providers.

Moreover, Liangyihui has proactively established a platform for oncology patient management and initiated the research and development of digital therapeutics for cancer, delivering high-quality, evidence-based online services to cancer patients while providing pharmaceutical companies with expanded solution offerings. This round of financing will accelerate Liangyihui’s strategic deployment of technological products within the oncology industry, leveraging innovative digital health models to effectively address the unmet clinical needs of patients.

Image from the official website of Liangyihui

With the public listings and sustained stock price increases of physician platforms represented by Medlive and Doximity, the value of specialized physician platforms that have been strengthening their core capabilities for years is gradually gaining market attention. Haoyue Capital is highly optimistic about the opportunities in next-generation medical services and the commercialization of pharmaceuticals and medical devices.

With the approval of innovative drugs, the traditional offline promotion models for novel digital therapeutics and innovative medical devices are no longer sufficient to meet the demands of current commercial competition. Pharmaceutical and medical device companies will increasingly rely on online promotional strategies. In this context, vertical emerging internet healthcare service providers, represented by Liangyihui, hold distinct advantages in understanding industry needs, penetrating various segments of the industrial chain, and delivering more specialized services, thereby facilitating easier commercial monetization.

LiangyihuiWe have stated that our years of dedication to the oncology field have given us firsthand insight into the needs, pain points, and challenges of clinical management. We have always been committed to providing cancer patients with effective diagnostic and treatment solutions that offer broader coverage, greater convenience, and enhanced sustainability. Cancer is currently the most significant disease threatening public health and represents the most dynamic and promising area for new drug development. For many years, Liangyihui has remained steadfast in its focus on building a specialized vertical platform for oncology, bringing together professional stakeholders across all sectors. We are dedicated to creating the most comprehensive learning and intellectual property (IP) platform for oncologists, providing patients with the most accessible medical services, and delivering the most complete marketing solutions for pharmaceutical companies.

Mr. Li Rui, Partner at Shunwei CapitalIt was stated that the Shunwei Capital team has long focused on the digital healthcare services sector and has successively invested in outstanding enterprises such as Liangyihui, DXY, Fangcun Doctor, and Kidney Online in recent years. Liangyihui boasts significant brand influence in the oncology field. It not only expands its reach through endorsements from top pharmaceutical companies with high repurchase rates and multi-form collaborations with leading experts but is also poised to deepen its market penetration through its unique business model. Amidst the current waves of digital pharmaceutical marketing and digital patient management, Liangyihui is well-positioned to become an industry leader and create long-term value.

Mr. Gao Jinda, Executive Director of Qiming Venture PartnersWe stated that oncology has always been a hotspot for medical innovation and a key focus of our investment; meanwhile, the online migration and digitalization of doctor-patient services represent a long-term trend. Through years of accumulation, Liangyihui has grown into China’s leading digital platform for oncology-related doctor-patient services, with its professional content and in-depth services highly recognized by physicians, patients, and pharmaceutical companies. We are honored to continue supporting Liangyihui in accelerating digital transformation in this field, thereby delivering richer, more precise, and smarter services to users.

Ms. Lu Qinchao, Founding and Managing Partner of Danlu CapitalIt stated that, leveraging its competitive advantages in the field of digital oncology marketing, Liangyihui has achieved rapid performance growth in recent years. Meanwhile, we also recognize the company’s proactive initiatives in other business units and consider Liangyihui an enterprise with long-term growth value. As the healthcare industry undergoes deepening digital transformation, we believe Liangyihui will continue to provide efficient and specialized solutions for pharmaceutical companies and hospitals, establishing itself as the leading service provider in the vertical niche of oncology.

Mr. Ding Yameng, Founding Partner of Haoyue CapitalIt was stated that the 2020 pandemic triggered a surge in digital pharmaceutical marketing. While digital drug marketing has already become a mature model abroad, and internet healthcare represents an inevitable global trend, this golden track in China finally reached an inflection point after five to six years of consolidation, catalyzed by the pandemic. We are optimistic about generalist platforms that have secured absolute leading positions, but even more bullish about the niche leaders remaining in each vertical sector after intense market consolidation. Oncology has consistently been the most dynamic field for innovative drug R&D globally. Liangyihui has evolved from content-led operations to technological innovation and data-driven solutions, becoming the preferred online platform for oncology patients and physicians. We have had the privilege of supporting the company through its Series C and C+ financing rounds, and we look forward to Liangyihui, as an innovative digital health platform in the oncology space, benefiting more patients.

Liangyihui is an authoritative academic platform for cancer care, the officially designated partner of the Chinese Society of Clinical Oncology (CSCO), and a strategic partner of the China Women's Development Foundation. It also maintains long-term, effective, and in-depth collaborations with many renowned hospitals and authoritative institutions both in China and abroad. Liangyihui is committed to addressing information asymmetry in the professional field, serving as an efficient tool for oncologists, while also acting as a comprehensive platform for public science education, cancer prevention, and cancer treatment for patients and the general public.

Shunwei Capital focuses on key sectors including mobile internet, Internet Plus, smart hardware, intelligent manufacturing, deep tech, consumer goods, enterprise services, and the electric vehicle ecosystem. Its representative portfolio companies in China and abroad include Xiaomi Group, Ninebot, Agora, iQIYI, NIO, ShareChat, Meesho, and over 400 other outstanding enterprises. By investing in visionary companies from the early to growth stages, Shunwei Capital aims to make our lives better.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages nine US dollar funds and six RMB funds, with total assets under management reaching $5.9 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as TMT and Healthcare. To date, Qiming Venture Partners has invested in more than 400 high-growth innovative enterprises, among which over 150 have achieved exits through listings on exchanges including the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange, the Taipei Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, as well as through mergers and acquisitions. More than 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

Danlu Capital is a venture capital firm dedicated to the healthcare and medical sector. Co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner of Fenxiang Investment Management, the firm has consistently deepened its focus on the early-stage healthcare and wellness landscape. It has systematically built a portfolio spanning innovative medical technologies—including high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health—as well as innovative drugs and novel healthcare services.

Haoyue Capital was established in January 2014, with a mission to serve as a bridge connecting China’s healthcare sector with capital markets. Its research coverage and transaction scope span multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, the firm publishes weekly healthcare investment reports and thematic research studies, offering Haoyue’s perspectives on new policies and emerging frontiers.